Genvor and Tuskegee University Announce Teaming Agreement to Advance Peptide Research and Sustainable Crop Protection Technologies

Rhea-AI Summary

Genvor (OTC: GNVR) entered a formal teaming agreement with Tuskegee University on December 2, 2025 to accelerate peptide-based technologies for sustainable crop protection.

The collaboration establishes joint research, testing, and grant-supported development, giving Genvor access to Tuskegee research laboratories, instrumentation, and student talent to expand scientific validation and field application of Genvor’s proprietary peptide active ingredients.

Market Reality Check

Price: $1.50 Vol: Volume 575 vs 20-day aver...

low vol

$1.50 Last Close

Volume Volume 575 vs 20-day average 853 suggests no unusual trading interest pre-news. low

Technical Price at 1.41 is below 200-day MA of 2.79 and 85.91% below 52-week high.

Peers on Argus

GNVR fell 28.23% while peers were mixed: PUBC down 30.62%, SGTM down 14.9%, othe...

GNVR fell 28.23% while peers were mixed: PUBC down 30.62%, SGTM down 14.9%, others flat, indicating stock-specific pressure rather than a broad sector move.

Market Pulse Summary

This announcement detailed a teaming agreement giving GNVR access to Tuskegee University’s laborator...

Analysis

This announcement detailed a teaming agreement giving GNVR access to Tuskegee University’s laboratories, scientific instrumentation, and students to accelerate peptide-based crop protection research. Recent regulatory filings showed GNVR as a pre-revenue agricultural biotechnology company with significant net losses and going-concern language, underscoring execution and funding risks. Investors may watch how this collaboration converts into validated field data, commercial partnerships, or licensing that could address the company’s limited cash position and development needs.

Key Terms

peptide, biological manufacturing, crop protection

3 terms

peptide medical

"pioneer in AI-accelerated peptide technology for sustainable agriculture"

A peptide is a short chain of amino acids — the small building blocks that make up proteins — linked together like a short necklace of beads. Investors care because peptides are used as drugs, diagnostic tools and research reagents: their size and structure can make them easier to manufacture, modify, patent and bring through clinical testing than large proteins, so progress or setbacks in peptide development can directly affect a biotech company's value.

biological manufacturing technical

"through advances in biological manufacturing and the discovery of novel sequences"

Biological manufacturing is the process of using living cells, microbes or biological systems to produce medicines, vaccines, enzymes and other biologically derived products; think of a factory that uses living organisms instead of machines to make complex therapies. It matters to investors because these operations are capital‑intensive, highly regulated and technically risky — success or failure in scaling production and meeting safety standards directly affects a company’s costs, supply reliability and revenue outlook.

crop protection technical

"peptide platforms beyond discovery and into field application, product validation, and sustainable agricultural practice."

Crop protection covers the products and practices—such as chemical treatments, biological controls, resistant seeds and farm methods—that keep crops safe from pests, weeds and disease. For investors it matters because these tools directly affect farm yields, input sales, regulatory risk and long-term demand for agricultural technology; think of crop protection as a shield that helps secure harvests and the revenues that depend on them.

AI-generated analysis. Not financial advice.

Woodland, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced it has entered into a formal teaming agreement with Tuskegee University, a premier research institution renowned for innovation in agricultural science and biotechnology. The collaboration seeks to fast-track next-generation peptide technologies through advances in biological manufacturing and the discovery of novel sequences that enhance crop protection, resilience, and nutrient performance.

The agreement establishes a cooperative framework for joint research, testing, and grant-supported development between Genvor and Tuskegee’s Center for Biomedical Research. The partnership provides Genvor access to university research laboratories, scientific instrumentation, and the next generation of agricultural scientists, enabling faster innovation cycles and expanded scientific validation of its proprietary active ingredients.

“This partnership marks a pivotal step in Genvor’s mission to enhance biological crop protection through the power of peptides,” said Chad Pawlak, Chief Executive Officer of Genvor. “Tuskegee University’s scientific excellence and access to world-class research facilities create the perfect environment to accelerate innovation and bring forward solutions that meet the demands of today's agricultural challenges.”

“Tuskegee University is known for solving the world’s most complex problems and this partnership with Genvor is a meaningful example of that,” said Dr. Mark A. Brown, President and CEO, Tuskegee University. “The research through this relationship exposes our students to crop protection and sustainable agriculture that may ultimately support farming across the country. Tuskegee University has entered its Renaissance Era and this kind of collaboration is a significant part of that.”

“Working with Genvor allows us to translate decades of peptide research into scalable, real-world impact,” said Dr. Jesse Jaynes, Professor of Biochemistry at Tuskegee University’s College of Agriculture, Environment, & Nutrition Sciences, College of Arts and Sciences and IBSC PhD Program and founding scientist behind Genvor’s core technologies. “This collaboration expands the reach of our peptide platforms beyond discovery and into field application, product validation, and sustainable agricultural practice.”

Dr. Timothy Turner, Associate Vice President for Research, Tuskegee University Center for Biomedical Research, added, “We’re thrilled to collaborate with Genvor in advancing peptide technology. The partnership not only deepens our applied research portfolio but also provides valuable training and experience for our students as they engage in innovation that has the potential to transform global agriculture.”

The teaming agreement underscores Genvor’s commitment to science-driven sustainability and strategic partnerships that amplify its impact in the biological crop protection sector. By bridging university research with commercial development, Genvor continues to strengthen its leadership in biologicals, crop resilience, and regenerative agricultural innovation.

About Genvor

Genvor, Inc. (OTC: GNVR) is a biotechnology company pioneering peptide-based solutions for crop protection and plant health. With a focus on sustainable agriculture, Genvor develops and commercializes biological actives that enhance crop performance, reduce chemical inputs, and support regenerative farming systems. Through its partnerships and technology platforms, Genvor is advancing a new era of natural, science-based crop protection For more information, visit www.genvor.com.

About Tuskegee University 

Located in Tuskegee, Alabama, Tuskegee University is a private, state-related and nationally ranked land-grant institution that serves a racially, ethnically and religiously diverse student body of 3,000-plus students. The institution was founded in 1881 by Booker T. Washington and is one of the nation's historically black colleges and universities (HBCUs). Accredited by the Southern Association of Colleges and Schools Commission on Colleges since 1933, Tuskegee’s academic programs — many accredited by their respective accrediting bodies — currently lead to 41 bachelor’s, 16 master’s and five doctoral degree opportunities. For more information about Tuskegee University, visit www.tuskegee.edu.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and projections about future events and are not guarantees of future performance. Forward-looking statements include, among others, statements regarding the potential benefits, outcomes, and scope of the collaboration between Genvor and Tuskegee University. Actual results may differ materially from those expressed or implied. Factors that could cause such differences include, but are not limited to, research results, funding outcomes, market adoption, and regulatory developments. Genvor undertakes no obligation to update or revise forward-looking statements, except as required by law.

Contacts:

Genvor, Inc.
Investor Relations & Media  
Carly Scaduto
carly@carlyscadutoconsulting.com

Tuskegee University
Thonnia Lee
Vice President of Strategic Communications 
tlee@tuskegee.edu

FAQ

What did Genvor (GNVR) announce on December 2, 2025 regarding Tuskegee University?

Genvor announced a formal teaming agreement with Tuskegee University to jointly advance peptide technologies for sustainable crop protection.

How will the GNVR–Tuskegee agreement affect Genvor’s R&D capabilities?

The agreement provides Genvor access to Tuskegee laboratories, scientific instrumentation, and student researchers to speed discovery and validation.

Does the GNVR teaming agreement include funding or grant collaboration?

Yes, the agreement establishes a framework for joint research, testing, and grant-supported development between the parties.

Will GNVR gain field validation opportunities from the Tuskegee partnership?

The collaboration is described as expanding peptide platforms into field application, product validation, and sustainable agricultural practice.

Who at Tuskegee is cited as supporting the GNVR collaboration?

Statements reference Dr. Mark A. Brown, Dr. Jesse Jaynes, and Dr. Timothy Turner as supporters and participants in the partnership.

What strategic benefit does Genvor (GNVR) expect from the Tuskegee teaming agreement?

Genvor expects accelerated innovation cycles, expanded scientific validation of proprietary active ingredients, and stronger ties to agricultural research talent.